Hepatitis B Vaccine Dosing and Schedule Recommendations
Adult Vaccination (Age ≥18 years)
- The Centers for Disease Control and Prevention recommends a 3-dose series (0, 1, and 6 months) for traditional vaccines or a 2-dose series (0 and 1 month) for Heplisav-B for adults ≥18 years 1, 2, 3
- For adults ≥20 years, the recommended dose for Recombivax HB is 10 μg (1.0 mL) per dose in a 3-dose schedule at 0, 1, and 6 months 1, 3
- For adults ≥20 years, the recommended dose for Engerix-B is 20 μg (1.0 mL) per dose in a 3-dose schedule at 0, 1, and 6 months 1, 3
- For adults ≥18 years, the recommended dose for Heplisav-B is 20 μg (0.5 mL) per dose in a 2-dose schedule at 0 and 1 month 1, 3
- For adults ≥18 years, the recommended dose for PreHevbrio is 10 μg (1.0 mL) per dose in a 3-dose schedule at 0, 1, and 6 months 1, 3
- The Centers for Disease Control and Prevention recommends that pregnant women receive Engerix-B, Recombivax HB, or Twinrix as Heplisav-B and PreHevbrio have insufficient data on vaccine-associated risks in pregnancy 1, 3, 4
Special Populations
- For hemodialysis patients and immunocompromised adults ≥20 years, the recommended dose for Recombivax HB is 40 μg (1.0 mL) per dose in a 3-dose schedule 1, 3
- For hemodialysis patients and immunocompromised adults ≥20 years, the recommended dose for Engerix-B is 40 μg (2.0 mL) per dose in a 4-dose schedule at 0, 1, 2, and 6 months 1, 3
Adolescent Vaccination (Ages 11-19 years)
- For adolescents aged 11-15, the recommended dose for Recombivax HB is 10 μg (0.5 mL) in either a 2-dose schedule at 0 and 4-6 months OR a 3-dose schedule at 0, 1, and 6 months 1, 3
- For adolescents aged 11-19, the recommended dose for Engerix-B is 10 μg (0.5 mL) per dose in a 3-dose schedule at 0, 1, and 6 months 1, 3
Alternative Schedules
- If the standard HepB vaccination schedule is interrupted, the series does not need to be restarted 1, 3
- For interrupted 3-dose series, the second and third doses should be separated by ≥8 weeks 1, 3
Administration Considerations
Common Pitfalls to Avoid
- Do not restart the series if the vaccination schedule is interrupted; simply continue where left off 1, 3
- Do not use Heplisav-B or PreHevbrio in pregnant women, hemodialysis patients, or children 1, 3, 4
- Do not assume serologic testing is required before vaccination; lack of testing should not be a barrier to vaccination 5, 6
Hepatitis B Vaccination Guidelines for Adults
Standard Vaccination Schedules
- The Advisory Committee on Immunization Practices (ACIP) recommends universal hepatitis B vaccination for all adults aged 19-59 years, with several approved vaccine options and schedules available depending on the specific product used 7
- For adults, the Twinrix vaccine can be administered in a standard schedule of 3 doses at 0, 1, and 6 months, or an accelerated schedule of 4 doses at 0 days, 7 days, 21-30 days, and 12 months, with the hepatitis B component being 20 μg per 1.0 mL injection 7, 8
Special Considerations
- Pregnant women requiring hepatitis B vaccination should receive only Engerix-B, Recombivax HB, or Twinrix, as Heplisav-B and PreHevbrio have insufficient safety data in pregnancy 7
Interrupted Vaccination Series
- If the vaccination schedule is interrupted, do not restart the series—simply continue where you left off, with the second and third doses separated by at least 8 weeks, and the final dose administered at least 8 weeks after the second dose and at least 16 weeks after the first dose 7, 8
Accelerated Schedules
- For individuals requiring rapid protection, an alternative 4-dose schedule can be used, with doses administered at 0, 1, 2, and 12 months, providing earlier seroprotection but requiring a fourth dose at 12 months for long-term protection 9
- The Twinrix accelerated schedule can be used, with doses administered at 0 days, 7 days, 21-30 days, and 12 months 7, 8
Pre-Vaccination Testing
- Pre-vaccination serologic testing is not required and should not be a barrier to vaccination, although testing for HBsAg, anti-HBs, and anti-HBc can be performed to identify those already immune 7
Age-Specific Recommendations
- The 2022 ACIP guidelines recommend universal hepatitis B vaccination for all adults aged 19-59 years, removing the previous requirement for risk factor assessment, and increasing vaccination coverage and decreasing hepatitis B cases 7
Hepatitis B Vaccine Administration and Response
Standard Dosing Regimens and Immune Response
- The Centers for Disease Control and Prevention recommends that a 3-dose series of hepatitis B vaccine produces a protective antibody response (≥10 mIU/mL) in >90% of healthy adults aged <40 years after completing the series 10, 11
- The 3-dose series produces a stepwise antibody response in healthy adults <40 years, with response rates declining with age—by age 60 years, only 75% achieve protective antibody levels even after completing the full series 10, 11
- Other factors reducing vaccine response include smoking, obesity, and immunosuppression 10, 11
Flexible Scheduling and Special Populations
- Alternative intervals of 0, 1, and 4 months OR 0, 2, and 4 months produce similar seroprotection rates to the standard 0, 1, 6-month schedule 10, 11
- Minimum acceptable intervals are 4 weeks between doses 1 and 2; 8 weeks between doses 2 and 3; 16 weeks between doses 1 and 3 11
- Routine serologic testing is not necessary for most adults, but testing for anti-HBs 1-2 months after series completion is recommended for certain groups, including healthcare and public safety workers, with a protective level of anti-HBs ≥10 mIU/mL 11
Hepatitis B Vaccination Guidelines
Special Populations
- For hemodialysis patients and immunocompromised adults aged ≥20 years, the Centers for Disease Control and Prevention recommends administering Engerix-B 40 μg (2.0 mL) at 0, 1, 2, and 6 months, achieving 67% seroprotection with a GMT of 93 mIU/mL among seroconverters, which is substantially lower than healthy adults, reflecting the impaired immune response in this population 12
- For HIV-infected adults without evidence of past or present HBV infection, the Infectious Diseases Society of America recommends administering either 40 μg Recombivax HB on a 3-dose schedule OR 40 μg Engerix-B (administered as 2 doses of 20 μg simultaneously) on a 4-dose schedule at 0, 1, 2, and 6 months, and testing for anti-HBs response 1-2 months after the third dose or at the next scheduled clinic visit 12
Hepatitis B Vaccination Scheduling and Monitoring Guidelines
1. Recommended Vaccine Formulations and Populations
- Heplisav‑B adult schedule: Administer 20 µg (0.5 mL) intramuscularly at month 0 and month 1, with a minimum interval of ≥ 4 weeks between doses. Both doses must be Heplisav‑B for the series to be considered valid. 13
- Pregnant women: Use only Engerix‑B, Recombivax HB, or Twinrix (standard 3‑dose schedule at 0, 1, 6 months). Heplisav‑B and PreHevbrio are not recommended because safety data in pregnancy are lacking. 13
2. High‑Risk Groups – Post‑Vaccination Serologic Testing
- Mandatory anti‑HBs testing 1–2 months after series completion for health‑care personnel, public‑safety workers with blood‑exposure risk, hemodialysis patients, and immunocompromised persons. A protective level is defined as anti‑HBs ≥ 10 mIU/mL. 14
- Annual anti‑HBs testing is advised for hemodialysis patients and immunocompromised individuals to monitor durability of protection. 14
- Booster vaccination should be given when anti‑HBs falls below 10 mIU/mL; after a booster, repeat anti‑HBs testing is not required. 14
3. Schedule Interval Requirements
- Minimum interval dose 1 → dose 2: 4 weeks.
- Minimum interval dose 2 → dose 3: 8 weeks.
- Minimum interval dose 1 → dose 3: 16 weeks.
- Final dose after the second dose must be administered ≥ 8 weeks later.
- Doses given ≤ 4 days before the required interval are still considered valid.
- There is no maximum interval between doses; series can be continued regardless of elapsed time. 14
4. Managing Interrupted or Mixed‑Brand Series
- Do not restart a hepatitis B series after an interruption; simply continue with the next scheduled dose. 14
- Switching vaccine brands within a series is permissible and does not require restarting the series. 14
5. Accelerated and Super‑Accelerated Schedules
- Standard accelerated 4‑dose schedule (0, 1, 2, 12 months) can be used when rapid protection is needed; the fourth dose at 12 months is essential for long‑term immunity. 14
- Twinrix super‑accelerated schedule (0 days, 7 days, 21–30 days, 12 months) is approved for combined hepatitis A/B protection; the usual 4‑day grace period does not apply to the first three doses. 14
6. Pre‑Vaccination Serologic Testing
- Routine pre‑vaccination testing is not required and must never delay vaccination. 14
- Targeted testing for HBsAg, anti‑HBs, and anti‑HBc may be considered in high‑risk populations (e.g., persons from regions with HBV endemicity ≥ 2 %, close contacts of HBsAg‑positive individuals, people who inject drugs). When such testing is performed, the first vaccine dose should be administered immediately after blood collection, without awaiting results. 14
7. Management of Non‑Responders
- Health‑care personnel whose anti‑HBs remains < 10 mIU/mL after a complete series should receive a second full series (typically six total doses) and have anti‑HBs re‑tested 1–2 months after the final dose. 14